Epigenetic targets in human neoplasms

Tamer E. Fandy, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

Epigenetic silencing of tumor suppressor genes is a salient feature of tumor cells. Re-expression of epigenetically silenced genes is a feasible and achievable strategy for cancer treatment. DNA methylation is the most characterized epigenetic silencing mechanism and the reversal of DNA methylation, genetically or pharmacologically, induces gene re-expression and proliferation arrest in tumor cells. Other epigenetic targets, such as histone acetylation and methylation, are also rational drug targets, and several small-molecule modulators of histone acetylation and methylation are currently under development or already in clinical trials. Epigenetic deregulation of miRNAs induces aberrant expression of miRNAs, which have been associated with the development and progression of cancer. The reversal of DNA methylation can induce the re-expression of miRNAs, and oligonucleotides can silence aberrantly expressed miRNAs. Evaluating the combination of different epigenetic modifiers and ensuring their optimization are the next challenges towards the establishment of epigenetic therapy.

Original languageEnglish (US)
Pages (from-to)221-232
Number of pages12
JournalEpigenomics
Volume2
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Epigenomics
MicroRNAs
DNA Methylation
Neoplasms
Acetylation
Histones
Methylation
Tumor Suppressor Genes
Oligonucleotides
Clinical Trials
Gene Expression
Pharmaceutical Preparations
Genes

Keywords

  • DNA methyltransferases inhibitor
  • epigenetics
  • epigenome
  • histone acetylation
  • histone methylation
  • miRNA

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Fandy, T. E., & Gore, S. D. (2010). Epigenetic targets in human neoplasms. Epigenomics, 2(2), 221-232. https://doi.org/10.2217/epi.10.1

Epigenetic targets in human neoplasms. / Fandy, Tamer E.; Gore, Steven D.

In: Epigenomics, Vol. 2, No. 2, 04.2010, p. 221-232.

Research output: Contribution to journalArticle

Fandy, TE & Gore, SD 2010, 'Epigenetic targets in human neoplasms', Epigenomics, vol. 2, no. 2, pp. 221-232. https://doi.org/10.2217/epi.10.1
Fandy, Tamer E. ; Gore, Steven D. / Epigenetic targets in human neoplasms. In: Epigenomics. 2010 ; Vol. 2, No. 2. pp. 221-232.
@article{432403344be44f138b393b8e0513adb9,
title = "Epigenetic targets in human neoplasms",
abstract = "Epigenetic silencing of tumor suppressor genes is a salient feature of tumor cells. Re-expression of epigenetically silenced genes is a feasible and achievable strategy for cancer treatment. DNA methylation is the most characterized epigenetic silencing mechanism and the reversal of DNA methylation, genetically or pharmacologically, induces gene re-expression and proliferation arrest in tumor cells. Other epigenetic targets, such as histone acetylation and methylation, are also rational drug targets, and several small-molecule modulators of histone acetylation and methylation are currently under development or already in clinical trials. Epigenetic deregulation of miRNAs induces aberrant expression of miRNAs, which have been associated with the development and progression of cancer. The reversal of DNA methylation can induce the re-expression of miRNAs, and oligonucleotides can silence aberrantly expressed miRNAs. Evaluating the combination of different epigenetic modifiers and ensuring their optimization are the next challenges towards the establishment of epigenetic therapy.",
keywords = "DNA methyltransferases inhibitor, epigenetics, epigenome, histone acetylation, histone methylation, miRNA",
author = "Fandy, {Tamer E.} and Gore, {Steven D.}",
year = "2010",
month = "4",
doi = "10.2217/epi.10.1",
language = "English (US)",
volume = "2",
pages = "221--232",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Epigenetic targets in human neoplasms

AU - Fandy, Tamer E.

AU - Gore, Steven D.

PY - 2010/4

Y1 - 2010/4

N2 - Epigenetic silencing of tumor suppressor genes is a salient feature of tumor cells. Re-expression of epigenetically silenced genes is a feasible and achievable strategy for cancer treatment. DNA methylation is the most characterized epigenetic silencing mechanism and the reversal of DNA methylation, genetically or pharmacologically, induces gene re-expression and proliferation arrest in tumor cells. Other epigenetic targets, such as histone acetylation and methylation, are also rational drug targets, and several small-molecule modulators of histone acetylation and methylation are currently under development or already in clinical trials. Epigenetic deregulation of miRNAs induces aberrant expression of miRNAs, which have been associated with the development and progression of cancer. The reversal of DNA methylation can induce the re-expression of miRNAs, and oligonucleotides can silence aberrantly expressed miRNAs. Evaluating the combination of different epigenetic modifiers and ensuring their optimization are the next challenges towards the establishment of epigenetic therapy.

AB - Epigenetic silencing of tumor suppressor genes is a salient feature of tumor cells. Re-expression of epigenetically silenced genes is a feasible and achievable strategy for cancer treatment. DNA methylation is the most characterized epigenetic silencing mechanism and the reversal of DNA methylation, genetically or pharmacologically, induces gene re-expression and proliferation arrest in tumor cells. Other epigenetic targets, such as histone acetylation and methylation, are also rational drug targets, and several small-molecule modulators of histone acetylation and methylation are currently under development or already in clinical trials. Epigenetic deregulation of miRNAs induces aberrant expression of miRNAs, which have been associated with the development and progression of cancer. The reversal of DNA methylation can induce the re-expression of miRNAs, and oligonucleotides can silence aberrantly expressed miRNAs. Evaluating the combination of different epigenetic modifiers and ensuring their optimization are the next challenges towards the establishment of epigenetic therapy.

KW - DNA methyltransferases inhibitor

KW - epigenetics

KW - epigenome

KW - histone acetylation

KW - histone methylation

KW - miRNA

UR - http://www.scopus.com/inward/record.url?scp=77954104642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954104642&partnerID=8YFLogxK

U2 - 10.2217/epi.10.1

DO - 10.2217/epi.10.1

M3 - Article

VL - 2

SP - 221

EP - 232

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 2

ER -